LaQuisa C. Hill, MD, on Relapsed or Refractory T-ALL: New Data on CD5 CAR T Cells
2023 ASCO Annual Meeting
LaQuisa C. Hill, MD, of Baylor College of Medicine, Houston Methodist Hospital, discusses study findings showing that CD5 chimeric antigen receptor (CAR) T cells may induce clinical responses in heavily treated patients with relapsed or refractory T-cell acute lymphoblastic leukemia. Manufacturing CD5 CAR T cells with tyrosine kinase inhibitors seemed to improve their potency and antitumor activity (Abstract 7002).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
LaQuisa C. Hill, MD:
The purpose of this study was a phase one clinical trial that was a dose escalation study using autologous CD5 CAR T for treatment of patients with relapse/ refractory T-cell ALL. In the initial cohort, we used our standard manufacturing practice that was overall very well-tolerated. However, in the eight patients initially treated, there were minimal responses seen with only one patient achieving a MRD positive remission.
We subsequently analyzed the cell products and determined that the CAR T cells had a significantly exhausted phenotype as a result of chronic CAR signaling. Therefore, we implemented a manufacturing change to include the use of TKI inhibitors dasatinib and ibrutinib in order to inhibit the chronic CAR signaling and saw a significant improvement in the naive T-cell repertoire and significant reduction in the number of exhausted T-cells in the final product. In the next cohort, we treated a total of seven patients, all manufactured using the TKI inhibition. And amongst those patients there was a total of four MRD negative remissions achieved out of seven patients treated.
The CAR T cell was well-tolerated in terms of CRS and ICANS. No grade-three events occurred. However, there was an increased risk of, or observation of, EBV reactivation with two patients developing PTLD. Currently it is unclear of the direct relationship to the CD5 CAR T cells manufactured with TKI. However, we plan to continue vigilant monitoring for this unexpected side effect and have instituted mitigation plans utilizing prophylactic rituximab as well as ensuring that patients have EBV-specific virus T cells available in the event that EBV reactivation occurs.
Moving forward, we will continue to try and optimize the CAR T cell product both for efficacy and safety and are looking into alternative immune effector subsets, such as virus-specific T cells as the immune factor cell of choice, as well as considering use of third-party or off-the-shelf T cells from healthy donors.
Related Videos
The ASCO Post Staff
Narjust Florez, MD, of Dana-Farber Cancer Institute, and Roy S. Herbst, MD, PhD, of Yale Cancer Center, discuss new phase III findings on osimertinib, a third-generation, central nervous system EGFR-TKI, which demonstrated an unprecedented overall survival benefit for patients with EGFR-mutated, stage IB–IIIA non–small cell lung cancer after complete tumor resection, with or without adjuvant chemotherapy (Abstract LBA3).
The ASCO Post Staff
Lisa A. Carey, MD, of the University of North Carolina at Chapel Hill, and Javier Cortes, MD, PhD, of the International Breast Cancer Center and Universidad Europea de Madrid, discuss phase II findings showing that one in three patients with HER2-positive early breast cancer may safely omit chemotherapy. Among the chemotherapy-free patients treated with trastuzumab and pertuzumab, the 3-year invasive disease–free survival was 98.8%, with no distant metastases (Abstract LBA506).
The ASCO Post Staff
Narjust Florez, MD, of Dana-Farber Cancer Institute, and Filippo Gustavo Dall’Olio, MD, of Institut Gustave Roussy, discuss circulating tumor DNA tumor fraction, and its link to survival in patients with advanced non–small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial. Tumor fraction was positive in 16% of patients randomly assigned to receive durvalumab in the study. This population seems to have a limited benefit from maintenance durvalumab after induction chemotherapy (Abstract 2516).
The ASCO Post Staff
Thomas E. Hutson, DO, PharmD, of Texas Oncology, discusses the 4-year follow-up results from the CLEAR study for patients with advanced renal cell carcinoma (RCC). The data showed that lenvatinib plus pembrolizumab continues to demonstrate clinically meaningful benefit vs sunitinib in overall and progression-free survival, as well as in overall and complete response rates, in first-line treatment (Abstract 4502).
The ASCO Post Staff
Jennifer A. Ligibel, MD, of Dana-Farber Cancer Institute, discusses a telephone-based weight loss intervention that induced clinically meaningful weight loss in patients with breast cancer who had overweight and obesity, across demographic and tumor factors. Additional tailoring of the intervention may possibly enhance weight loss in Black and younger patients as well (Abstract 12001).